Steve Usdin

Selina Koch, neuroscience and psychiatry editor who interviews industry leaders. Steve Usdin, policy analyst focused on FDA and biomedical funding. Danielle Golovin, analyst tracking Series A and VC trends. They discuss 2025 Series A stabilization and which modalities drew funding. They debate how compounded Wegovy affects innovation and cover Congress defending NIH budgets. They explore serendipity versus engineering in psychiatric drug discovery.

Danielle Golovin, a Senior Biopharma Analyst specializing in induced proximity technologies, shares her insights on the evolution of next-generation targeting chimeras (TACs). She discusses the surge in publications driving this analysis and highlights specific innovations like lysosomal degraders. Steve Usdin, Washington Editor, dives into the political landscape surrounding drug pricing policies, including MFN legislation and its implications for the pharma industry. The duo also examines GSK's $2.2 billion acquisition of Rapt Therapeutics, discussing its strategic significance.

Steve Usdin, Washington editor covering policy and FDA moves. Lauren Martz, oncology biomarker and cell therapy development expert. Paul Benanos, dealmaking and cell therapy commercialization analyst. They discuss Gilead’s $7.8B acquisition of Arcellx and its implications. They explore ctDNA as a potential surrogate endpoint and the validation, standardization and trial hurdles that remain.

Simone Fishburn, geopolitics and life‑sciences policy commentator; Selena Koch, editorial strategist on industry trends; Steve Usdin, policy and regulatory analyst; Lauren Martz, biopharma intelligence lead on RNA and renal. They unpack RNAi and antisense as 2026 catalysts. They cover cardiovascular Lp(a) trials, renal and neuromuscular readouts, obesity launches, and China’s new orphan drug exclusivity rule.

This week, Steve Usdin, Washington editor, and Lauren Martz, Biopharma Intelligence Executive Director, dive into the hot topics of biotech. They analyze significant deals from the J.P. Morgan Healthcare Conference, including a bispecific partnership between AbbVie and RemeGen. Usdin provides a bold policy outlook, warning of changes to drug pricing norms and potential FDA staff losses. Martz discusses approval trends for 2025, emphasizing innovations in drug delivery and the unique pressures affecting orphan drug programs. Tune in for new insights on biopharma dynamics!